Posted by Michael Wonder on 27 Oct 2022
MSD's Zerbaxa becomes Korea's newest antibiotic to receive reimbursement
27 October 2022 - MSD Korea is strengthening its position in the local antibiotic market with Zerbaxa (ingredient: ceftolozane/tazobactam) after winning reimbursement for the new drug on 1 October.
While Sivextro was the only antibiotic that won insurance benefits in the past decade (2016), Dong-A ST gave up launching the drug as its low price yielded a small profit.
